EP2043688A4 - Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists - Google Patents

Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Info

Publication number
EP2043688A4
EP2043688A4 EP07813400A EP07813400A EP2043688A4 EP 2043688 A4 EP2043688 A4 EP 2043688A4 EP 07813400 A EP07813400 A EP 07813400A EP 07813400 A EP07813400 A EP 07813400A EP 2043688 A4 EP2043688 A4 EP 2043688A4
Authority
EP
European Patent Office
Prior art keywords
tumors
treatment
growth factor
receptor antagonists
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07813400A
Other languages
German (de)
French (fr)
Other versions
EP2043688A2 (en
Inventor
Eric Rowinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Publication of EP2043688A2 publication Critical patent/EP2043688A2/en
Publication of EP2043688A4 publication Critical patent/EP2043688A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07813400A 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists Withdrawn EP2043688A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83348706P 2006-07-27 2006-07-27
PCT/US2007/074448 WO2008014386A2 (en) 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Publications (2)

Publication Number Publication Date
EP2043688A2 EP2043688A2 (en) 2009-04-08
EP2043688A4 true EP2043688A4 (en) 2009-11-11

Family

ID=38982334

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07813400A Withdrawn EP2043688A4 (en) 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Country Status (15)

Country Link
EP (1) EP2043688A4 (en)
JP (1) JP2009544736A (en)
KR (1) KR20090033841A (en)
CN (1) CN101484186A (en)
AU (1) AU2007279261A1 (en)
BR (1) BRPI0712368A2 (en)
CA (1) CA2654911A1 (en)
CR (1) CR10486A (en)
EA (1) EA200870603A1 (en)
EC (1) ECSP089011A (en)
MX (1) MX2008016187A (en)
NO (1) NO20085182L (en)
TN (1) TNSN08512A1 (en)
WO (1) WO2008014386A2 (en)
ZA (1) ZA200810600B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3135043A1 (en) * 2019-03-27 2020-10-01 National Research Council Of Canada Anti-egfrviii antibodies and antigen-binding fragments thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COMBS STEPHANIE E ET AL: "Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 18 May 2006 (2006-05-18), pages 133, XP021016124, ISSN: 1471-2407 *
FURMAN W L: "A Phase I Study of Gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors", J CLIN ONCOL, vol. 22, no. 14S, 2004, pages 8521, XP002540583, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/8521> [retrieved on 20090807] *
KREMPIEN R ET AL: "Randomized phase II - study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol [ISRCTN56652283]", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 5, no. 1, 11 October 2005 (2005-10-11), pages 131, XP021004738, ISSN: 1471-2407 *

Also Published As

Publication number Publication date
WO2008014386A3 (en) 2008-07-03
ZA200810600B (en) 2009-11-25
AU2007279261A1 (en) 2008-01-31
MX2008016187A (en) 2009-01-20
WO2008014386A2 (en) 2008-01-31
CN101484186A (en) 2009-07-15
EA200870603A1 (en) 2009-06-30
ECSP089011A (en) 2009-01-30
BRPI0712368A2 (en) 2012-06-05
KR20090033841A (en) 2009-04-06
EP2043688A2 (en) 2009-04-08
TNSN08512A1 (en) 2010-04-14
CR10486A (en) 2009-02-23
JP2009544736A (en) 2009-12-17
NO20085182L (en) 2009-04-24
CA2654911A1 (en) 2008-01-30

Similar Documents

Publication Publication Date Title
IL281715A (en) Activin-actriia antagonists and uses for promoting bone growth in cancer patients
HRP20190092T1 (en) Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
IL211952A0 (en) Implantable device for the delivery of risperidone and methods of use thereof
EP2131919A4 (en) Implantable device for communicating with biological tissue
PT2426148E (en) Anti-il-3ra antibody for use in treatment of blood tumor
BRPI1007877A2 (en) &#34;dpp-iv inhibitors for the treatment of diabetes in pediatric patients&#34;
IL230911A0 (en) Apparatus for treating cardiac tissue and use thereof
IL213410A0 (en) Methods and compositions for diagnostic use in cancer patients
EP1991284A4 (en) Bioimplants for use in tissue growth
IL197157A0 (en) Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
HK1203160A1 (en) Tapentadol for the treatment of pain in arthrosis (tapentadol)
ZA201102949B (en) Implantable device for the delivery of octreotide and methods of use thereof
HK1209053A1 (en) Use of dimiracetam in the treatment of chronic pain
PL2227210T3 (en) Patient bed with monitoring- and therapy device
EP2421548A4 (en) Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
PL2320900T3 (en) Opioids for use in the treatment of resistant cancer patients
EP2271267A4 (en) Medical devices for delivering fluids during surgery and methods for their use
EP2334304A4 (en) Therapeutic bone growth and regeneration
GB0822486D0 (en) Compounds for use in the treatment of pain
ZA200810600B (en) Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
EP2124950A4 (en) Treatment of pain with naloxone
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
EP2336108A4 (en) Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses
GB0809329D0 (en) Depsipeptides and their therapeutic use
EP2183357A4 (en) Tissue organizing structure and therapeutic methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20091014

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100112